LivaNova PLC (NASDAQ:LIVN) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 80.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,815 shares of the company’s stock after buying an additional 7,049 shares during the period. Intech Investment Management LLC’s holdings in LivaNova were worth $831,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hexagon Capital Partners LLC increased its position in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after acquiring an additional 370 shares during the period. Fifth Third Bancorp grew its stake in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of LivaNova during the first quarter valued at $84,000. Canada Pension Plan Investment Board bought a new stake in shares of LivaNova during the second quarter valued at about $88,000. Finally, Central Pacific Bank Trust Division acquired a new stake in LivaNova in the third quarter worth about $178,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Up 3.5 %

Shares of LivaNova stock opened at $52.48 on Friday. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a market capitalization of $2.85 billion, a PE ratio of 124.95 and a beta of 1.01. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock’s fifty day moving average is $52.24 and its 200-day moving average is $52.30.

Wall Street Analyst Weigh In

LIVN has been the topic of several research analyst reports. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Robert W. Baird boosted their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.